Updated 2023-10-26

ABOUT HANSA BIOPHARMA

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases and gene therapy. Hansa Biopharma is based in Lund, Sweden with operations in Europe and in the U.S.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES



[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al. New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
[4] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard at Charité Universitätsmedizin Berlin

STRATEGIC PRIORITIES

Commercialize Idefirix® in first indications and markets

- Successfully launch Idefirix® in Europe
- Secure FDA approval and launch Idefirix® in the U.S.
- Geographical expansion

Advance ongoing imlifidase clinical programs in transplantation and autoimmune diseases

- Achieve approval/usage of imlifidase in follow-on indications
- Broaden our Idefirix® label beyond kidney transplantation

Expand IgG-cleaving enzyme technology platform into new disease areas and indications

- Explore gene therapy opportunity
- Explore opportunities in Oncology and stem cell transplantation (HSCT)
- Develop our next generation IgG-cleaving enzymes to allow for recurring treatment

ACHIEVED AND UPCOMING MILESTONES

2023

9M 2023

- **U.S. ConfideS (Kidney tx) Phase 3:** Continued enrollment beyond 64 patients
- **Anti-GBM disease Phase 3:** First patient enrolled
- **GBS Phase 2:** Complete enrollment
- **ANCA-associated vasculitis Phase 2:** First patient enrolled
- **HNSA-5487 (Lead NiceR candidate):** Initiate Phase 1 study
- **Genethon Crigler-Najjar:** Initiate preclinical study with imlifidase prior to GNT-0003

Q4 2023

- **HNSA-5487 (Lead NiceR candidate):** High-level data readout from Phase 1
- **Long-term follow-up (Kidney tx):** 5-year data readout
- **GBS Phase 2:** First data readout
- **AMR Phase 2:** Full data readout
- **Sarepta DMD pre-treatment Phase 1b:** Commence clinical study

2024

- **GBS Phase 2:** Outcome of the comparative efficacy analysis to IGOS data
- **Genethon Crigler-Najjar Phase 1/2:** Initiate clinical study with imlifidase prior to GNT-0003
- **HNSA-5487 (Lead NiceR candidate):** Further analysis around endpoints to be completed in 2024 incl. lead indication
- **U.S. ConfideS (Kidney tx) Phase 3:** Complete randomization

2025

- **U.S. ConfideS (Kidney tx) Phase 3:** BLA submission

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarters	Lund, Sweden
Operations	Europe and the U.S.
Employees	168

Key Executives

Peter Nicklin	Chairman
Søren Tulstrup	President & CEO
Donato Spota	SVP & CFO
Matthew Shaulis	CCO & U.S. President
Hitto Kaufmann	*Joins Hansa as CSO on Dec. 1 '23*

MARKET DATA (Q3 2023)

Market Cap	USD ~173m (Sept 2023)
52 Week Range	SEK 34-76
Avg. Daily Turnover	vol. 248k shares
Shares Outstanding	52m

Top 5 Shareholders	**(% S/O)**
Redmile Group	20.3%
Nexttobe AB	4.1%
Thomas Olausson	3.7%
Fjärde AP-Fonden (AP 4)	3.6%
Avanza Pension	3.4%

SHARE PRICE CHART (12M)



KEY FINANCIALS

SEKm	2021	2022	9M'23	Q3'23
Revenue	34	155	84	23
R&D cost	-231	-346	-303	-96
Net loss	-548	-610	-707	-251
Cash & Short investment	889	1,496	908	908
Operating Cash Flow	-481	-504	-583	-194
Employees	133	150	168	168

** Unaudited*

CALENDAR

Oct 26, 2023	Interim Report for January-September 2023
Nov 21, 2023	SEB Healthcare Seminar 2023, Stockholm
Nov 23, 2023	Redeye Life Science Day, Stockholm
Dec 6, 2023	Carlsquare Life Science Investor Day, Stockholm
Dec 14, 2023	Redeye Investor Forum, Gothenburg
Jan 8, 2024	JPM week, San Francisco
Feb 2, 2024	Full-year Report for January-December 2023
Feb 28, 2024	Ökonomisk Ugebrev Life Science Event, Cph
Mar 20, 2024	Annual Report 2023
Apr 17, 2024	Interim Report for January-March 2024
July 17, 2024	Half-year Report January-June 2024
Oct 23, 2024	Interim Report for January-September 2024

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Stephanie Kenney
VP Global Corp. Affairs
M: +1 (484) 319 2802
stephanie.kenney@hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATING PATHOGENIC IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection



Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



OUR BUSINESS MODEL



Evolution into a fully integrated biopharmaceutical company

Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing in 2024